A Phase I Trial Of VNP40101M [laromustine], A Novel Alkylating Agent, For Patients With Hematologic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs Laromustine (Primary)
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 02 Jan 2008 Status changed from in progress to completed.
- 25 Sep 2005 New trial record.